Dr. Siegall is a key researcher & specialist in oncology matters, and the president & CEO of Seattle Genetics, an association with wide experience in drug improvement, research and scientific advancement. Clay has a broad knowledge and mastery in therapeutic medication advancement and doing research in cancer. Siegall pursued Bachelor’s degree in Zoology from Maryland University in addition to Genetics Ph.D. at George Washington University. The achievements enabled Siegall to have a solid establishment in biotechnology field with his career portfolio getting rich on daily basis. Sometime recently, Siegall operated at National Institute of Health, National Cancer Institute & Bristol-Myers Squibb Pharmaceutical Research Institute. Later, he assisted in establishing Seattle Genetics right after leaving Bristol-Myers Squibb Pharmaceutical Research Institute. His basic drive for the establishment of Seattle Genetics was to cater for the gap in the field of oncology. Moreover, he has rolled out different key improvements in that very field.
Presently, Dr. Siegall has over 70 products with his name, has 15 licenses and is a member in various boards for various pharmaceutical organizations and cancer research enterprises that fuse yet not obliged to Alder Pharmaceuticals Inc, Ultragenyx Pharmaceutical & Washington Biotech. Under his initiative, Seattle Genetics created Adcetris – Brentuximab Vedotin which is an anticancer medication and that is antibody-based. The medication got certification from FDA and it is used as a part of the organization of untreated or the recently dissected Hodgkin lymphoma. More so, the drug has been approved for use in more than sixty countries. Adcetris was produced in a joint exertion with Takeda Pharmaceutical Company. The organization endeavors didn’t stop there. At this moment, they are working on other anti-cancer products with 33A being part of the same and utilized in curing myeloid leukemia.
Subsequently to Dr. Siegall achievements and that of organization, it is basic that media outlets have been talking about of his accomplishments. In addition, he is usually part of the hot topics in social media, medicinal services and business online journals. The summary entails however not confined to Bloomberg, CNBC, dockofthetrays.com, Business Insider, & hacronym.com. In citrate.org blog, Siegall is depicted as a great example and key pioneer to other biotechnological associations. Likewise, bizjournals.com depicts the specialist as driven and one who is represents an incredible role in research against cancer.